Ejner Knud Moltzen

This inventor holds 30 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 1 EPO patent, primarily in Pharmaceutical Chemistry. Top assignees: H. Lundbeck A/s, Other. Active years: 1989-2020.

USPTO Granted Patents = 30 (Patent Applications = 1)

% Patents Active = 60.0

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 1

Average Co-Inventor Count = 3.5

ph-index = 7

Forward Citations = 237(Granted Patents)

Location History:

Frederiksberg, DK (1989 - 1997)
Frederiksberg C, DK (1997 - 2001)
Gentofte, DK (1997 - 2020)

Company Filing History:

28 out of 513

H. Lundbeck A/s

patents

2 out of 834,411

Other

patents

Years Active: 1989-2020

Loading Chart...

Areas of Expertise:

Serotonin Reuptake Inhibitors

Piperazine Derivatives

Indole Derivatives

Anxiolytic Compounds

Heteroaryl Derivatives

Fused Benzo Compounds

Glycine Transport Inhibitors

Dimeric Piperidine

Piperidine Derivatives

Oxazole Derivatives

Thiazole Derivatives

Triazole Compounds

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10844029 - Phenyl-piperazine derivatives as serotonin reuptake inhibitors (2020-11-24),

2. 9708280 - Phenyl-piperazine derivatives as serotonin reuptake inhibitors (2017-07-18),

3. 9090575 - Phenyl-piperazine derivatives as serotonin reuptake inhibitors (2015-07-28),

4. 8110567 - Phenyl-piperazine derivatives as serotonin reuptake inhibitors (2012-02-07),

5. 7683053 - Phenyl-piperazine derivatives as serotonin reuptake inhibitors (2010-03-23),

6. 7393845 - Heteroaryl derivates, their preparation and use (2008-07-01),

7. 7342015 - Indole derivatives (2008-03-11),

8. 7144884 - Phenyl-piperazine derivatives as serotonin reuptake inhibitors (2006-12-05),

9. 7138407 - Phenyl-piperazine derivatives as serotonin reuptake inhibitors (2006-11-21),

10. 6921774 - Compounds and their use as glycine transport inhibitors (2005-07-26),

11. 6727263 - Indole and 2,3-dihydroindole derivatives, their preparation and use (2004-04-27),

12. 6699864 - Substituted phenyl-piperazine derivatives, their preparation and use (2004-03-02),

13. 6596722 - Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use (2003-07-22),

14. 6514993 - Serotonin 5-HT1A and dopamin D2 receptor ligands (2003-02-04),

15. 6476035 - Indole and 2,3-dihydroindole derivatives, their preparation and use (2002-11-05),

Certainly! Here is an article about inventor Ejner Knud Moltzen:

Title: Spotlight on Inventor Ejner Knud Moltzen from Gentofte, DK

Introduction:

Ejner Knud Moltzen, a prolific inventor hailing from Gentofte, Denmark, has made significant contributions to the field of pharmaceuticals with an impressive portfolio of 30 patents. His innovative work in developing compounds for the treatment of affective disorders has garnered attention in the scientific community.

Latest Patents:

One of Ejner Knud Moltzen's latest patents includes the groundbreaking invention of Phenyl-piperazine derivatives as serotonin reuptake inhibitors. These compounds, represented by the general formula I, have shown promise in the treatment of various affective disorders such as depression, anxiety disorders (including general anxiety disorder and panic disorder), and obsessive-compulsive disorder.

Career Highlights:

Throughout his career, Ejner Knud Moltzen has been associated with esteemed pharmaceutical companies such as H. Lundbeck A/S, where he has played a vital role in drug discovery and development. His expertise and dedication to innovative research have been instrumental in advancing the field of pharmacology.

Collaborations:

Ejner Knud Moltzen has had the opportunity to collaborate with renowned colleagues in the industry, including Jens Kristian Perregaard and Kim Andersen. Together, they have worked on pioneering projects that have shaped the landscape of pharmaceuticals and enhanced patient care.

Conclusion:

In conclusion, Ejner Knud Moltzen's remarkable journey as an inventor underscores his profound impact on the field of pharmaceuticals. His passion for innovation, coupled with his technical acumen, has led to the development of groundbreaking compounds that have the potential to transform the treatment of affective disorders. We look forward to witnessing more innovative contributions from this visionary inventor in the future.